{
    "2021-08-27": [
        [
            {
                "time": "2021-08-26",
                "original_text": "A股融资融券日报：两融余额增加5.84亿元（8月26日）",
                "features": {
                    "keywords": [
                        "两融余额",
                        "增加"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-25",
                "original_text": "沃森生物上半年净利润3.2亿同比增超4倍，mRNA新冠疫苗已处于III期临床阶段",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "净利润",
                        "同比增",
                        "mRNA新冠疫苗",
                        "III期临床"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-25",
                "original_text": "沃森生物：上海泽润在北京设立全资子公司 投建重组新型冠状病毒疫苗(CHO细胞)产业化项目",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "上海泽润",
                        "全资子公司",
                        "重组新冠疫苗",
                        "产业化项目"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-25",
                "original_text": "沃森生物：拟投建重组新型冠状病毒疫苗（CHO细胞）产业化项目",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "重组新冠疫苗",
                        "产业化项目"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-25",
                "original_text": "沃森生物与蓝鹊生物共同开展流感病毒mRNA疫苗产品开发及商业化合作",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "蓝鹊生物",
                        "流感病毒mRNA疫苗",
                        "产品开发",
                        "商业化合作"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-25",
                "original_text": "沃森生物：上半年净利润同比增419% 加快新冠疫苗的临床和产业化进度",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "净利润",
                        "同比增",
                        "新冠疫苗",
                        "临床",
                        "产业化"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-25",
                "original_text": "沃森生物上半年净利升419.09%至3.19亿元",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "净利",
                        "同比升",
                        "3.19亿元"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-25",
                "original_text": "沃森生物半年报：上半年净利3.19亿元 同比增419%",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "半年报",
                        "净利",
                        "同比增",
                        "3.19亿元"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-25",
                "original_text": "沃森生物：签署呼吸道合胞病毒mRNA疫苗产品开发及商业化合作协议",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "呼吸道合胞病毒",
                        "mRNA疫苗",
                        "产品开发",
                        "商业化合作"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}